Liquid biopsy and single cell technology firm Menarini Silicon Biosystems said Wednesday that it will begin offering a circulating tumor cell test to Alivio Health clients and providers.
Menarini’s blood-based Cellsearch CTC test will allow longitudinal monitoring of cancer patients during the course of the disease, the firm said. The tests will provide information about a patient's cancer at diagnosis and during therapy, enabling doctors to make more informed and timely decisions about optimizing the therapeutic strategy, Menarini added.
Specifically, among the over 200,000 members of Alivio Health's participating health plans, patients with cancer will now have access to more accurate, timely, affordable, and reimbursable liquid biopsy tests, Menarini said.
Financial and other terms of the agreement were not disclosed.
The test is U.S. Food and Drug Administration (FDA)-cleared for capturing and enumerating circulating tumor cells in cancer patients with metastatic breast, prostate, and colorectal cancer. New Cellsearch laboratory-developed tests are also available to clinicians for CTC enumeration and HER2 and PD-L1 targeted therapy-associated biomarker analysis in patients with various solid tumors, as well as for patients with melanoma and multiple myeloma, Menarini said.
